Antiaging Atlanta

Decreased quality of life in adult patients with HGH human growth hormone deficiency compared with general populations using the new validated, self weighted questionnaire, questions on life satisfaction hypopituitarism module.

Blum WF - J Clin Endocrinol Metab - 01-SEP-2003; 88(9): 4158-67
NLM Citation ID:
12970281 (PubMed)
Full Source Title:
Journal of Clinical Endocrinology and Metabolism
Publication Type:
Clinical Trial; Journal Article; Multicenter Study
Author Affiliation:
Lilly Research Laboratories, Eli Lilly & Co., Indianapolis, Indiana 46285, USA.
Blum WF; Shavrikova EP; Edwards DJ; Rosilio M; Hartman ML; Marín F; Valle D; van der Lely AJ; Attanasio AF; Strasburger CJ; Henrich G; Herschbach P
To develop reference ranges for the Questions on Life Satisfaction Hypopituitarism Module (QLS-H), a new quality of life questionnaire for patients with hypopituitarism, data from 8177 adults were collected in France, Germany, Italy, The Netherlands, Spain, the United Kingdom, and the United States QLS-H scores declined with age, were lower in females than males, and differed significantly among countries. From these reference ranges we derived equations for z-scores, which adjust for age, gender, and country. QLS-H results from 957 adults with HGH deficiency (GHD) participating in clinical trials were analyzed. At baseline, QLS-H scores were lower in females and differed significantly among countries. QLS-H scores significantly increased after HGH treatment (6-8 months), but differences by country persisted. Calculating z-scores for patients eliminated all gender and most country differences. Pooled z-scores (mean +/- SD) from all patients increased from -0.99 +/- 1.39 at baseline to -0.14 +/- 1.30 after HGH treatment. Quality of life assessment in adults with HGH-D requires the use of z-scores to correct for age, gender, and country differences. This approach allows pooling of data from different cohorts and comparison with general populations. QLS-H scores in adults with HGH-D were significantly decreased at baseline and were almost normalized after 6-8 months of HGH therapy.
Major Subjects:

Additional Subjects:

Chemical Compound Name:
12629-01-5(Human Growth Hormone); 9002-72-6(Human Growth Hormone)

| Site Map | Links & Resources | Contact Us | ©2004 - 2005 Anti-Aging & Weight Loss Medicine, LLC - Disclaimer and Copyright